Description
Details
Product Overview
MSCgo™ Rapid Osteogenic Differentiation Medium is a serum-free (SF), xeno-free (XF), complete, and ready to use formulation developed for optimal differentiation of human mesenchymal stem cells (hMSC) to mature osteocytes. The MSCgo™ Rapid Osteogenic Differentiation Medium is validated to efficiently differeniate hMSC from a variety of sources, including bone marrow (BM-MSC), adipose tissue (AT-MSC), and umbilical cord tissue (UC-MSC). The MSCgo™ Rapid Osteogenic Differentiation protocol is part of a complete system for multipotency evaluation of hMSCs. The MSCgo™ Rapid Osteogenic Differentiation Medium enables fast osteogenesis if hMSCs. Differentiation to mature osteocytes is seen in less than 10 days.
Features
- Serum-free, xeno-free solution
- Complete differentiation medium
- Ready-to-use, simple protocol
- Rapid osteogenic differentiation (less than 10 days)
- Contains stable L-alanyl-L-glutamine
- Does not contain antibiotics
Osteogenesis Results
Osteogenic differentiation of hMSC results in the formation of mineralized culture with calcified nodules and calcium secretion that can be detected with Alizarin Red S (ARS) staining. The ARS is used to stain calcium deposits formation which are an indication of mature osteocytes. The amount of calcified nodules formation and calcium secretion can be varying using different hMSC (e.g. source, age, and passage number).
Specifications
Specifications
| QTY | 100 mL |
|---|---|
| Form | Liquid |
| Brand | MSCgo™ |
| Storage Conditions | 2 to 8°C |
| Shipping Conditions | Cold Pack |
| Quality Control | The MSCgo Rapid Osteogenic Differentiation Medium is validated for optimal differentiation of hMSC into osteocytes. Additional tests are: pH, osmolality, endotoxins and sterility tests. |
| Specifications | Required Materials for Osteogenic Assay
|
| Legal | For human ex vivo tissue and cell culture processing applications. This reagent is not approved for human or animal use, or for application of in vitro diagnostic procedures. |
References
references
- D. Kamiya et al. Induction of functional xeno-free MSCs from human iPSCs via a neural crest cell lineage. npj Regenerative Medicine, 2022
- X. Kang et al. Zuogui Wan slowed senescence of bone marrow mesenchymal stem cells by suppressing Wnt/β-catenin signaling. Journal of Ethnopharmacology, 2022
- N.I. Enukashvily, et al. Fibrin Glue Implants Seeded with Dental Pulp and Periodontal Ligament Stem Cells for the Repair of Periodontal Bone Defects: A Preclinical Study. Bioengineering 2021, https://doi.org/10.3390/bioengineering8060075
- L. Zhang, et.al. LGALS3BP/Gal-3 promotes osteogenic differentiation of human periodontal ligament stem cells. Archives of Oral Biology, 2021, https://doi.org/10.1016/j.archoralbio.2021.105149.
- Y. Matsuo, et al. Isolation of adipose tissue-derived stem cells by direct membrane migration and expansion for clinical application. Human Cell (2021). https://doi.org/10.1007/s13577-021-00505-3
- S. Kikuchi, et al. Development of a nasal mucosa-removal model for evaluating cell therapy. Regenerative Therapy, Volume 16, 2021, P. 32-41, ISSN 2352-3204, https://doi.org/10.1016/j.reth.2020.12.004.
- S. Uchida, et al. mRNA as a Tool for Gene Transfection in 3D Cell Culture for Future Regenerative Therapy Micromachines 2020, 11, 426; doi:10.3390/mi11040426 www.mdpi.com/journal/micromachines
- A. Picken, et al. A Monte Carlo framework for managing biological variability in manufacture of autologous cell therapy from mesenchymal stromal cells therapies. Cytotherapy 27 February 2020 https://doi.org/10.1016/j.jcyt.2020.01.006
- Y.T. Hsiaoa, et al. Neuromedin U (NMU) regulates osteoblast differentiation and activity. Biochemical and Biophysical Research Communications Available online 11 February 2020, https://doi.org/10.1016/j.bbrc.2020.02.003
- X. Wang, et al. Exosomes influence the behavior of human mesenchymal stem cells on titanium surfaces Biomaterials, 24 October 2019, https://doi.org/10.1016/j.biomaterials.2019.119571
- Y. Ben et al. STABILIZED AMORPHOUS CALCIUM CARBONATE FOR TREATMENT OF NEUROLOGICAL , MUSCULAR AND INFERTILITY DISEASES OR CONDITIONS . US Patent App. 16/069,762, 2019
- J. Leber et al., Microcarrier choice and bead-to-bead transfer for human mesenchymal stem cells in serum-containing and chemically defined media. Process Biochemistry, volume 59, Part B, August 2017, Pages 255-265
- L. Pu et al., Compared to the amniotic membrane, Wharton’s jelly may be a more suitable source of mesenchymal stem cells for cardiovascular tissue engineering and clinical regeneration. Stem Cell Research & Therapy 2017 8:72
Documentation
Materials Safety Data Sheet
Manuals and Protocols
MSCgo™ Rapid Osteogenic Differentiation Medium Instructions for UseProduct Literature
Certificate of Analysis
COA's can be downloaded from Sartorius's Certificates Portal.
For certificates issued before November 15, 2021, please enter below the product lot number and click search.
